Mira Pharmaceuticals Inc
MIRA
Company Profile
Business description
Mira Pharmaceuticals Inc is a clinical-stage pharmaceutical development company focused on developing novel oral small-molecule therapeutics for neurologic, neuropsychiatric, metabolic, and inflammatory disorders. The company's pipeline includes three product candidates: Ketamir-2, MIRA-55, and SKNY-1, three drug candidates designed to address unmet medical needs across neuropathic and inflammatory pain, central nervous system disorders, and metabolic and behavioral conditions. The company operates as a single operating and reportable segment.
Contact
1200 Brickell Avenue
Suite 1950 No. 1183
MiamiFL33133
USAT: +1 786 432-9792
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2026
Employees
2
Stocks News & Analysis
stocks
Anthropic and OpenAI face commodification threats. Here’s what to watch for
Frontier AI labs face a three-pronged set of challenges.
stocks
Berkshire Hathaway: Abel pushes into new territory with Bending Spoons investment
We think it is a sign that the firm is finally moving out of its comfort zone to find places to put capital to work.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,975.70 | 35.30 | 0.39% |
| CAC 40 | 7,844.89 | 111.81 | -1.41% |
| DAX 40 | 25,339.89 | 282.72 | -1.10% |
| Dow JONES (US) | 52,002.41 | 175.28 | -0.34% |
| FTSE 100 | 10,785.36 | 96.54 | -0.89% |
| HKSE | 24,186.83 | 124.11 | 0.52% |
| NASDAQ | 26,140.03 | 572.99 | -2.14% |
| Nikkei 225 | 64,916.70 | 407.59 | -0.62% |
| NZX 50 Index | 13,652.07 | 101.66 | -0.74% |
| S&P 500 | 7,659.44 | 84.62 | -1.09% |
| S&P/ASX 200 | 8,845.70 | 39.00 | 0.44% |
| SSE Composite Index | 3,716.28 | 8.81 | 0.24% |